Adrenal Washout Calculator | CT Scan Analysis

Adrenal Washout Calculator

Calculate absolute and relative washout percentages to help differentiate adrenal adenomas from other adrenal lesions using CT imaging data.

Results

Absolute Washout Percentage (AWP)
Relative Washout Percentage (RWP)

What do these results mean?

How to Use This Calculator

Using this adrenal washout calculator is straightforward. You’ll need three Hounsfield Unit (HU) measurements from your CT scan:

  • Pre-contrast attenuation: This is the baseline measurement taken before any contrast material is administered. It shows the natural density of the adrenal lesion.
  • Post-contrast attenuation: Measured during the portal venous phase, typically 60-70 seconds after contrast injection. This captures peak enhancement.
  • Delayed attenuation: Taken 10-15 minutes after contrast administration. This shows how much contrast remains in the lesion.

Simply enter these three values into the corresponding fields and click “Calculate Washout” to get your results instantly.

What Are Adrenal Nodules?

Adrenal nodules are masses found in the adrenal glands, often discovered incidentally during imaging for unrelated conditions. They’re surprisingly common, appearing in 2-7% of the general population and becoming more frequent with age.

Most adrenal nodules are benign and don’t produce hormones, but some can be problematic. Here’s what they might be:

  • Adenomas: Benign tumors that are the most common type. They typically wash out contrast quickly.
  • Metastases: Cancer spread from other organs like lung, breast, or kidney. These tend to retain contrast longer.
  • Pheochromocytomas: Rare tumors that produce adrenaline-like hormones.
  • Adrenal carcinomas: Rare malignant tumors that are aggressive.
  • Other lesions: Including cysts, hemorrhages, or myelolipomas.

The washout calculator helps distinguish between these different types based on how they handle contrast material.

The Science Behind Washout Analysis

Adrenal washout analysis works on a simple principle: different tissue types handle contrast material differently. Benign adenomas are rich in lipids and have a unique cellular structure that allows contrast to wash out rapidly. Malignant lesions and metastases typically have different vascular patterns and cellular compositions, causing them to retain contrast longer.

Calculation Formulas

Absolute Washout Percentage (AWP):

AWP = [(Post-HU – Delayed-HU) / (Post-HU – Pre-HU)] × 100

Relative Washout Percentage (RWP):

RWP = [(Post-HU – Delayed-HU) / Post-HU] × 100

Interpretation Thresholds

Measurement Threshold Interpretation
Absolute Washout ≥ 60% Strongly suggests benign adenoma
Relative Washout ≥ 40% Strongly suggests benign adenoma
Absolute Washout < 60% May indicate non-adenomatous lesion
Relative Washout < 40% May indicate non-adenomatous lesion

When either AWP is ≥60% or RWP is ≥40%, the lesion is very likely a benign adenoma. However, these thresholds aren’t absolute—clinical context, patient history, and other imaging features must always be considered.

Clinical Applications

This calculator serves multiple purposes in clinical practice:

  • Characterizing indeterminate lesions: When an adrenal nodule has intermediate attenuation (10-30 HU) on unenhanced CT, washout analysis can clarify whether it’s likely benign.
  • Cancer staging: In patients with known malignancies, distinguishing adrenal metastases from benign adenomas affects treatment planning.
  • Reducing unnecessary procedures: Confident diagnosis of benign adenomas can prevent needless biopsies or surgeries.
  • Guiding follow-up: Results help determine whether a lesion needs monitoring, additional testing, or intervention.

When Washout Analysis Works Best

Adrenal washout calculation is most reliable when specific conditions are met:

  • The lesion is at least 1 cm in diameter—smaller nodules can be difficult to measure accurately
  • The CT protocol follows standard timing: portal venous phase at 60-70 seconds and delayed phase at 10-15 minutes
  • The lesion is homogeneous—areas of necrosis, hemorrhage, or calcification can skew results
  • Proper region of interest (ROI) placement over the most solid portion of the lesion
  • Consistent contrast dosing and injection rates
Note: Some pheochromocytomas (30-45%) can show washout characteristics similar to lipid-poor adenomas. However, pheochromocytomas rarely show lipid content (< 10 HU on unenhanced CT), which helps differentiate them.

Limitations and Considerations

While powerful, washout analysis has limitations you should be aware of:

Lipid-poor Adenomas

About 30% of adenomas are lipid-poor and may not meet standard washout thresholds. These can appear indeterminate and might need MRI with chemical shift imaging for confirmation.

Hypervascular Metastases

Metastases from renal cell carcinoma, hepatocellular carcinoma, or melanoma can be hypervascular and occasionally show washout patterns similar to adenomas, though this is uncommon.

Heterogeneous Lesions

Nodules with mixed attenuation, necrosis, or hemorrhage are challenging to evaluate. Recent studies suggest washout CT may have reduced accuracy in heterogeneous nodules where mixed attenuation occupies more than 20% of the volume.

Size Matters

Lesions larger than 4 cm have a higher likelihood of being malignant regardless of washout characteristics and often warrant closer investigation.

Pre-contrast Attenuation

A pre-contrast attenuation greater than 43 HU in a non-calcified, non-hemorrhagic lesion raises suspicion for malignancy, regardless of washout values.

Comparing Different Imaging Approaches

Method Best For Limitations
Unenhanced CT (< 10 HU) Lipid-rich adenomas Misses lipid-poor adenomas
Washout CT Indeterminate lesions (10-30 HU) Requires contrast and delayed imaging
MRI Chemical Shift Detecting intracellular lipid More expensive, less available
PET/CT Suspected metastases or pheochromocytoma High cost, radiation exposure

Each method has its place. Washout CT is particularly valuable as a middle ground—more specific than simple unenhanced CT but less complex and costly than MRI or PET.

Common Questions

Why do I need three different CT measurements?
Each measurement captures a different phase of contrast behavior. The pre-contrast value establishes the baseline, the post-contrast shows peak enhancement, and the delayed phase reveals how much contrast has washed out. Together, they create a complete picture of the lesion’s contrast kinetics.
Can this calculator replace a doctor’s diagnosis?
No. This calculator is an educational resource and diagnostic aid. Results should always be interpreted by a qualified radiologist or physician who can consider your complete clinical picture, including symptoms, medical history, lab results, and other imaging findings.
What if my results are borderline?
Borderline results (AWP 55-65% or RWP 35-45%) can be challenging. Your doctor might recommend additional imaging like MRI with chemical shift sequences, endocrine testing if a functional tumor is suspected, or follow-up CT to monitor for changes over time.
How accurate is washout analysis?
When properly performed, washout CT has high sensitivity and specificity for diagnosing adenomas. Studies show AWP ≥60% has approximately 86-88% sensitivity and 92-96% specificity for adenomas. RWP ≥40% shows similar accuracy. However, accuracy depends on proper imaging technique and appropriate patient selection.
Do I need to fast before a washout CT?
Typically, you’ll be asked to fast for 4-6 hours before the exam since intravenous contrast is used. Your imaging facility will provide specific preparation instructions. Be sure to inform your doctor about any kidney problems, as contrast can affect kidney function.
How long does the entire scan take?
The actual scanning takes only a few minutes, but since the delayed phase is acquired 10-15 minutes after contrast injection, you’ll need to wait at the imaging center during this interval. Plan for about 30-45 minutes total.
What happens if neither threshold is met?
When both AWP < 60% and RWP < 40%, the lesion doesn't meet criteria for a benign adenoma. This doesn't automatically mean it's malignant—it could be a lipid-poor adenoma, pheochromocytoma, metastasis, or other entity. Further evaluation is typically recommended.
Are there any risks to washout CT?
The main risks are related to contrast administration: allergic reactions (rare), kidney effects (especially in those with pre-existing kidney disease), and radiation exposure from CT. Your doctor will weigh these risks against the benefits of obtaining a diagnosis.

Case Examples

Case 1: Classic Benign Adenoma

A 58-year-old patient has an incidentally discovered 2.5 cm right adrenal nodule. CT measurements show:

  • Pre-contrast: 18 HU
  • Post-contrast: 95 HU
  • Delayed: 35 HU

Results: AWP = 77.9%, RWP = 63.2%

Interpretation: Both values exceed thresholds, strongly suggesting a benign lipid-poor adenoma. No further workup needed; routine follow-up may be considered.

Case 2: Possible Metastasis

A 65-year-old patient with history of lung cancer has a 3 cm left adrenal mass. Measurements:

  • Pre-contrast: 32 HU
  • Post-contrast: 88 HU
  • Delayed: 75 HU

Results: AWP = 23.2%, RWP = 14.8%

Interpretation: Low washout values suggest this is not an adenoma. Given the patient’s cancer history and elevated pre-contrast attenuation, this is concerning for metastasis. PET/CT or biopsy recommended.

Case 3: Borderline Results

A 52-year-old patient with a 1.8 cm adrenal nodule shows:

  • Pre-contrast: 22 HU
  • Post-contrast: 102 HU
  • Delayed: 55 HU

Results: AWP = 58.8%, RWP = 46.1%

Interpretation: AWP is just below threshold, but RWP exceeds it. This is likely a benign adenoma, though chemical shift MRI could provide additional confirmation if there’s clinical concern.

When to Consider Additional Testing

Even with washout results, some situations call for further evaluation:

  • Lesions larger than 4 cm (higher malignancy risk regardless of washout)
  • Rapid growth on follow-up imaging (> 5 mm per year)
  • Concerning features: irregular margins, heterogeneous appearance, or invasion into surrounding structures
  • Clinical suspicion of hormone-producing tumors (hypertension, unexplained weight gain, etc.)
  • Known malignancy elsewhere with atypical washout patterns
  • Pre-contrast attenuation > 43 HU in non-hemorrhagic, non-calcified lesions

Your healthcare provider will determine the appropriate next steps based on your individual situation.

References

Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-1460. doi:10.2214/AJR.10.4547
Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222(3):629-633. doi:10.1148/radiol.2223010766
Patel J, Davenport MS, Cohan RH, Caoili EM. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol. 2013;201(1):122-127. doi:10.2214/AJR.12.9577
Schieda N, Siegelman ES. Update on CT and MRI of adrenal nodules. AJR Am J Roentgenol. 2017;208(6):1206-1217. doi:10.2214/AJR.16.17758
Choi YA, Kim CK, Park BK, et al. Evaluation of adrenal metastases from renal cell carcinoma and hepatocellular carcinoma: use of delayed contrast-enhanced CT. Radiology. 2013;266(2):514-520. doi:10.1148/radiol.12120110
Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology. 2006;238(2):578-585. doi:10.1148/radiol.2382041514
Corwin MT, Badawy M, Caoili EM, et al. Incidental adrenal nodules in patients without known malignancy: prevalence of malignancy and utility of washout CT for characterization-a multi-institutional study. AJR Am J Roentgenol. 2023;220(1):77-84. doi:10.2214/AJR.22.27901
Nandra G, Duxbury O, Patel P, et al. Technical and interpretive pitfalls in adrenal imaging. Radiographics. 2020;40(4):1041-1060. doi:10.1148/rg.2020190080
Corwin MT, Caoili EM, Elsayes KM, et al. Performance of CT with adrenal-washout protocol in heterogeneous adrenal nodules: a multiinstitutional study. AJR Am J Roentgenol. 2024;222(5):e2330769. doi:10.2214/AJR.23.30769
Scroll to Top